CRISPR Therapeutics provides pipeline update: CTX310 advances to Phase 1b; zugo-cel shows durable remission in SLE

CRISPR Therapeutics AG

CTX310 (ANGPTL3) advanced to Phase 1b for severe hypertriglyceridemia and refractory hypercholesterolemia after positive Phase 1 data.
CTX320 (LPA) showed up to 73% reduction in dose escalation; next-gen CTX321 with ~2-fold greater potency in preclinical testing.
Zugo-cel (CTX112): first SLE patient in drug-free DORIS remission at month 9; second SLE patient with SLEDAI-2K 0 at month 2.
Collaboration with Eli Lilly to evaluate zugo-cel + pirtobrutinib in aggressive B-cell lymphomas.
Next-gen diabetes candidate CTX213 progressing towards clinic after promising CTX211 data showing C-peptide at 12 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.